Is Gland Pharma (GLAND) overvalued or fairly valued?

MarketChacha shows Gland Pharma's valuation in context — a forward P/E of about 26.7, a price-to-book of about 3.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Gland Pharma's revenue?

Gland Pharma reported revenue of ₹6,431 Cr for FY2026, with net profit of ₹1,027 Cr, per official filings.

What is the share price of Gland Pharma (GLAND)?

Gland Pharma last traded at ₹2,439.10 (-0.8% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Gland Pharma

GLAND · NSE · Pharma · India

₹2,439.10-0.8%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerGLAND

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersHyderabad, India

Market cap₹40,235 Cr

P/B3.9

Volume6.71L

Websitewww.glandpharma.com

Filings tracked0

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Profile as reported by Yahoo Finance.

Who owns it

Promoters51.8%
Institutions34.0%
Public & other14.2%

67 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Net margin trend21.5% → 16.0%

Margin has compressed by about 5.6 points over the period — profitability is trending down.

Growth qualityrev 21% · PAT 10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,736 Cr · EPS 16.89

Est. earnings growth +51.5%

Next fiscal year

Rev ₹8,319 Cr · EPS 91.19

Est. earnings growth +22.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,573.6052-wk range₹2,573.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹40,235 Cr

Day change

-0.8%

Fwd P/E

26.7

P/B

3.9

Div yield

0.81%

Beta

0.48

Revenue (FY2026)

₹6,431 Cr

Net margin

16.0%

Revenue CAGR (3y)

+21.1%

Profit CAGR (3y)

+9.6%

Net profit (FY2026)

₹1,027 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about GLAND

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,431 Cr	₹1,027 Cr	16.0%
FY2025	₹5,617 Cr	₹699 Cr	12.4%
FY2024	₹5,665 Cr	₹772 Cr	13.6%
FY2023	₹3,625 Cr	₹781 Cr	21.5%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹1,743 Cr	₹367 Cr	21.0%
2025Q4	₹1,695 Cr	₹261 Cr	15.4%
2025Q3	₹1,487 Cr	₹184 Cr	12.4%
2025Q2	₹1,506 Cr	₹215 Cr	14.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.